Second malignancies among waldenstrom macroglobulinemia patients: Small samples and sparse data

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 542-543

  Ojha, R P ^a   Thertulien, R ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Cancer Centers of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLON CANCER; CONFIDENCE INTERVAL; DATA ANALYSIS; HUMAN; ITALY; KIDNEY CANCER; LARGE CELL LYMPHOMA; LETTER; LUNG CANCER; MELANOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; SAMPLE SIZE; SECOND CANCER; SYSTEMATIC ERROR; UTERUS CANCER; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84856342151     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr537     Document Type: Letter

References (4)

1. Varettoni M, Tedeschi A, Arcaini L et al. Risk of second cancers in Waldenstrom macroglobulinemia. Ann Oncol 2012; 23: 411-415.
2. Poole C. Low P-values or narrow confidence intervals: which are more durable? Epidemiology 2001; 12(3): 291-294.
3. Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol 2000; 151(5): 531-539.
4. National Cancer Institute; United States National Institutes of Health. Surveillance, Epidemiology and End Results Data. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/data/ (2 August 2011, date last accessed).